Professor Louisa Degenhardt – UNSW Australia
Although based in Australia, Degenhardt has a prolific and wide-ranging background of scholarship and research into many pertinent areas of my project including the use of methadone vs. Suboxone in treatment of opiate addiction, and a broad background in the mechanics of addiction.
Lianping (Mint) Ti – BC Centre for Excellence in HIV/AIDS
Ti is a research scientist with the in Vancouver. She has researched how access to healthcare and harm reduction services impact people who use drugs, and was given a Canadian Institute of Health Research Rising Star Award, and her research is currently supported by a CIHR Fellowship.
Richard S Schottenfeld, MD – Yale University (Psychiatry)
His research is aimed at improving opiate maintenance treatment, specifically alternatives to methadone including other drugs like Suboxone combined with behavioral therapies. He is also concerned with the issue of access to opiate treatment in office and primary care setting to expand the availability of help to addicts.
Ingrid Binswanger, MD, MPH, MS – UC Denver
Studies prevention of opiate overdose, naloxone to prevent death in overdoses, and criminal justice involvement and its relationship to health.
Marc Fisher – Senior editor at Washington Post
Has written a bunch of articles about treatment and how it is to access and quit opiates.
Prof. Stacey Sigmon – UVM
In addition to studying the behavioral and phamacological treatment of opiate dependence, Sigmon studies the intersection of mental health and substance use, which is a huge aspect of addiction. Behavioral and pharmacological treatment of opioid dependence; Novel formulations of
Caleb J. Banta-Green, PhD – University of Washington, Alcohol and Drug Abuse Institute
Has done a ton of work on overdose prevention as well as well as many other relevant topics including how public health law affects overdoses.
Professor Richard P. Mattick – Drug and Alcohol Studies in the National Drug & Alcohol Research Centre at the University of New South Wales, Sydney
Has authored more than 100 articles and books on emotional, cognitive, and psychological problems. He currently focuses on treatment of young drug dependent people, and the efficacy of different pharmacological treatment methods for opiate dependence.
Daniel Alford, MD – BU public health big shot
(Copied directly from his online bio due to lengthy affiliations)
Alford is the Director of the Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program at Boston University School of Medicine (BUSM). He is on staff in the Section of General Internal Medicine and is director of the Clinical Addiction Research and Education (CARE) Unit and Medical Director of the Office-Based Opioid Treatment (OBOT) program and Massachusetts Screening, Brief Intervention, Referral to Treatment Training and Technical Assistance (MASBIRT TTA) program at Boston Medical Center (BMC). He is a diplomate in Addiction Medicine by the American Board of Addiction Medicine. He is president of the Association for Medical Education and Research in Substance Abuse (AMERSA) an interdisciplinary organization of leaders in substance use education, research, and policy. He is the chair of the American Society of Addiction Medicine (ASAM) Buprenorphine Course for Office-Based Treatment of Opioid Use Disorders Planning Committee. He is course director of the Chief Resident Immersion Training Program in Addiction Medicine funded by the National Institute on Drug Abuse (NIDA).
In 2015 he was appointed to the Massachusetts Governor’s Opioid Drug Formulary Commission. He was recognized as a Champion of Change by the White House and in 2014 received the national AMA “Award for Health Education.”
Joseph Moses – DEA special agent and agency spokesman
Moses is cited in numerous articles on opiates, and has a 20+ history as a special agent. Building a relationship with him will be crucial for accessing DEA info and other officials.
Megan McKee 